Last reviewed · How we verify

DANICOPAN — Competitive Intelligence Brief

DANICOPAN (DANICOPAN) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement Factor D Inhibitor. Area: Other.

marketed Complement Factor D Inhibitor Complement Factor D Other Small molecule Live · refreshed every 30 min

Target snapshot

DANICOPAN (DANICOPAN). Danicopan is a selective inhibitor of complement Factor D, preventing the cleavage of Factor B and the formation of the C3 convertase in the alternative complement pathway.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DANICOPAN TARGET DANICOPAN marketed Complement Factor D Inhibitor Complement Factor D 2024-01-01
CYB704 CYB704 Sandoz phase 3 Complement Factor D inhibitor Complement Factor D

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Complement Factor D Inhibitor class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DANICOPAN — Competitive Intelligence Brief. https://druglandscape.com/ci/danicopan. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: